First human tests begin for experimental drug TEV-56286
NCT ID NCT07674940
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety and how the body handles TEV-56286 (also known as emrusolmin or anle138b) in healthy adults. Participants receive either single or multiple rising doses of the drug or a placebo. The study measures how the drug is absorbed, distributed, and eliminated, and monitors for any side effects. Results will help determine safe doses for future studies in people with diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TEV-56286 (emrusolmin, anle138b)
What this could lead to
If safe and well-tolerated, this could pave the way for future studies testing TEV-56286 as a treatment for diseases like Parkinson's or other protein-aggregation disorders.
What could go wrong
This is an early, first-in-human trial in healthy volunteers, so it cannot show whether the drug works for any disease. Side effects or poor tolerability may stop further development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••